|
|
|
 |
 |
|
|
|
Twice each month at Noon EST on Sunday, Stockprowler will bring you his latest hot stock pick...free on the Web! Stockprowler uses state of the art technology to look under the rocks and find those little stocks with the potential to make the BIG moves. Stockprowler screens primarily NYSE, AMEX, and NASDAQ stocks trading around $3 or under. These stocks offer considerable leverage at minimal cost. It is not uncommon for these stocks to make moves of 30%, 50%, or more. Please read our disclaimer before trading in any stocks mentioned on this Web site. So are you ready? Here's the Stockprowler report for the week of Sunday, January 17, 2001: |
| ||||||||||||||||
| Greenspan jolted the economy and the stock market by
lowering short-term interest rates by 50 basis points before the next
scheduled Fed meeting at the end of January. It was also the first time
that Greenspan had changed Fed policy with a move bigger than 25 basis
points. What spooked Greenspan to act so quickly and decisively? It
appears to be the news that consumers weren’t buying at Christmas time and
that retailers were projecting very disappointing earnings. If it is true
that the consumer provides the earliest clues to where the economy is
headed… then we are headed for trouble. It is expected that Greenspan will
cut interest rates again at the end of the month and continue to cut rates
over the next several months to stave off a recession… the wild card on
the horizon is OPEC.
Stockprowler’s last pick, RAZF, closed Friday at 2 1/8 up over 30% since we profiled it on December 31. Previous pick, IRSN, is showing signs it may be ready to move… we expect the company’s breakthrough Electronic Film System will be huge. Also, readers may want to check out Infotopia (IFTP), a company that is topping our Watch List this week. IFTP is a direct marketer of health and fitness products and has been growing revenues at an eye-popping rate through its highly successful infomercials. Though it is a Bulletin Board stock, the company expects to be listed on the Nasdaq in early 2001. IFTP announced a stock buyback on Friday…
http://biz.yahoo.com/bw/010112/ma_infotop_2.html Stockprowler’s
pick this week is… Henley
Healthcare, Inc. (Nasdaq: HENL) Corporate
Web Site: http://www.henleyhealth.com/ Shares
Outstanding: 15.2 million Public
Float: 7.0 million Insider
Ownership: 54% Institutional
Ownership: (3) less than 1% Market
Capitalization: $3.8 million Closing Price Friday: $0.25 If
you have ever watched an old episode of Star Trek from the 60’s you were
undoubtedly amazed at how quickly and simply health problems were able to
be treated. Doctors placed a small device over the afflicted area and the
patient got well… no surgery, no cutting, no bleeding. But Star Trek was
just a futuristic TV show, and the amazing device was pure fantasy. Well,
it looks like fantasy may have become reality. A company in Sugar Land,
Texas has developed a small hand-held low energy laser device that has
demonstrated remarkable healing powers and may revolutionize the treatment of
injuries and chronic disease…
Henley Healthcare, Inc.
(Nasdaq: HENL), formerly Lasermedics, Inc., develops,
manufactures and distributes products and related accessories used in the
control of acute or chronic pain.
The company has over 300 products that compete in substantially all
segments of the rehabilitation products market, offering cost-effective
alternatives to surgery and drugs. Henley has operating units which are
categorized by the type of service provided and type of product
manufactured or distributed. The clinical unit manufactures and markets a
diversified line of pain management products used in clinical settings for
both physical therapy and rehabilitation as well as other applications.
The training unit consists of Health Career Learning Systems which provides training and safety
products and technical support necessary to meet federal Occupational
Safety and Health Act (OSHA) compliance standards and also coordinates the
training of medical professionals in the use of various other products
offered by the company. The international unit, acquired in 1998, consists
of Enraf-Nonius of Denmark which designs, manufactures and markets a
variety of ultra-sound and electrical stimulation
products. Henley is
currently awaiting
FDA approval on its MicroLight 830(TM), a hand-held, low-energy
(non-surgical) laser for the treatment of repetitive stress disorders such
as carpal tunnel syndrome.
The MicroLight 830(TM) is manufactured by CB Svendsen, a Danish company,
which has sold its low level laser devices in more than 20 foreign
countries to physicians, physical therapists, dermatologists and
veterinarians, for use in connection with wound healing, pain reduction
and anti-inflammatory indications. Henley has worked on the development
and marketing of the MicroLight 830(TM) with CB Svendsen since June 1991.
In March 1997, Henley and CB Svendsen entered into new agreements pursuant
to which CB Svendsen was paid $100,000 and Henley obtained unto perpetuity
the sole and exclusive world-wide distribution rights to all low level
laser devices manufactured by or for CB Svendsen. In connection with these
agreements, Henley is required to pay a 3 percent royalty on revenue
generated by the company on sales of the applicable products.
Henley distributes the Microlight 830(TM) to various clinicians participating in the company's research program under its Investigational Device Exemption ("IDE") as allowed by FDA regulations. Lasers that do not exceed 100 milliwatts have no thermal effect on living tissue. However, depending on the wavelength, the low-level laser light will penetrate and act on the tissue underlying the skin. The specific wavelength of the laser incorporated within the Microlight 830(TM) penetrates the dermis, epidermis and subcutaneous layers of the skin to a depth of more than 1 inch. Along its path, the laser deposits photons, packets of light energy, into the cells, which is believed to stimulate nerve regeneration, reduce swelling and improve micro-circulation by bringing increased oxygen and blood flow to the problem area. The light also blocks pain enzymes and activates the synthesis of pain reducing endorphins. The company believes that the Microlight 830(TM) is an effective treatment for carpal tunnel syndrome (CTS), which is the tendon and nerve damage that results from the fast, forceful wrist and hand motions that are repeated in production and manufacturing workplaces many times in each day, such as operating a computer, cutting meat, cutting or plucking poultry or assembling automobiles. Conventional surgical and non-surgical treatments for CTS and other repetitive stress injuries have been for the most part unsuccessful in allowing CTS sufferers to continue with or return to productive employment. As a result of the limited success of these treatments, CTS frequently results in temporary or permanent disability at substantial economic costs. Henley believes that the potential market for the Microlight 830(TM) could exceed $2 billion worldwide and encompasses hospitals, clinics, medical doctors, chiropractors, physical therapists, dentists, veterinarians and, ultimately, individuals. OSHA statistics put the number of workers experiencing musculoskeletal injuries due to repetitive motion, overexertion, or awkward workstation postures at 1,800,000 each year in the U.S. alone. The cost to businesses is estimated at $20 billion a year. There are several foreign as well as U.S. manufacturers of low energyThe company estimates that it will incur expenditures approximating $500,000 for research and development, in the event it obtains FDA approval for human application of the Microlight 830(TM). Such research and development effort will primarily emphasize additional photobiostimulation applications for the Microlight 830(TM), such as pain suppression, wound healing and sports injuries, in various medical disciplines including general medicine, dentistry, veterinary medicine, physical therapy, orthopedic surgery, dermatology and re-constructive and cosmetic surgery. The Microlight 830(TM) has been classified by the FDA as a "non-significant risk" Class III medical device and, as such, the company is allowed to conduct clinical trials under an approved IDE. The clinical trials are subject to IDE regulations, including record keeping, adverse event reporting and other clinical study requirements. The objective of these clinical trials is to evaluate the therapeutic effects of low-level laser energy in pain management, soft tissue trauma (including RSI) and dental applications. The company is sponsoring independent research studies on the effects of the Microlight 830(TM) at various clinical sites in the U.S. Stockprowler readers are encouraged to review the relevant research studies and articles available at the following links: http://www.henleyhealthcare.com/microlight/microlight.htm http://www.henleyhealthcare.com/microlight/noninvasive.htm |
|
|
